NAS:CNTB (USA)
Â
ordinary shares
$
1.295
-0.0050 (-0.39%)
10:08 PM EST
Business Description
Connect Biopharma Holdings Ltd
NAICS : 541713
SIC : 2834
ISIN : KYG235491019
Share Class Description:
CNTB: ordinary sharesTotal Employee Number:
62Description
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 52.83 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -13.99 | |||||
Beneish M-Score | 10.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 21.4 | |||||
3-Year EPS without NRI Growth Rate | 22 | |||||
3-Year FCF Growth Rate | 21.6 | |||||
3-Year Book Growth Rate | -36.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 470.96 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.07 | |||||
9-Day RSI | 29.71 | |||||
14-Day RSI | 33.05 | |||||
3-1 Month Momentum % | 21.5 | |||||
6-1 Month Momentum % | -10.66 | |||||
12-1 Month Momentum % | 50.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 2.37 | |||||
Cash Ratio | 1.93 | |||||
Days Sales Outstanding | 122.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -14.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2384.49 | |||||
Net Margin % | -2336.3 | |||||
EBITDA Margin % | -2361.29 | |||||
FCF Margin % | -2084.12 | |||||
OCF Margin % | -2082.26 | |||||
ROE % | -144.83 | |||||
ROA % | -111.38 | |||||
ROIC % | -950.36 | |||||
3-Year ROIIC % | -591.97 | |||||
ROC (Joel Greenblatt) % | -1563.3 | |||||
ROCE % | -146.35 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 27.35 | |||||
PB Ratio | 2.98 | |||||
Price-to-Tangible-Book | 3.01 | |||||
EV-to-EBIT | -0.73 | |||||
EV-to-EBITDA | -0.74 | |||||
EV-to-Revenue | 17.05 | |||||
EV-to-Forward-Revenue | 3.75 | |||||
EV-to-FCF | -0.82 | |||||
| Price-to-Net-Current-Asset-Value | 3.7 | |||||
| Price-to-Net-Cash | 5.4 | |||||
Earnings Yield (Greenblatt) % | -136.99 | |||||
FCF Yield % | -76.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNTB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Connect Biopharma Holdings Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.953 | ||
| EPS (TTM) ($) | -1.196 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 33.05 | ||
| 14-Day ATR ($) | 0.259401 | ||
| 20-Day SMA ($) | 1.98875 | ||
| 12-1 Month Momentum % | 50.93 | ||
| 52-Week Range ($) | 1.061 - 3.82 | ||
| Shares Outstanding (Mil) | 62.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Connect Biopharma Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Connect Biopharma Holdings Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 53 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 11:30 | 1.73 (-3.63%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 2.24 (+4.19%) | ||
| H.C. Wainwright 4(th) Annual BioConnect Investor Conference | 2026-05-19 09:30 | 2.38 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 2.34 (-0.85%) | ||
| Biotech Resurgence: Platforms and Pipelines of Today\'s Innovators | 2026-04-16 14:00 | 2.93 (-4.87%) | ||
| Annual report for 2025 | 2026-03-31 | 2.90 (-19.89%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 2.90 (-19.89%) | ||
| Connect Biopharma Conference Call | 2026-03-30 08:00 | 3.45 (-6.76%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 08:00 | 2.65 (+5.16%) |
Show
Entries
Connect Biopharma Holdings Ltd Frequently Asked Questions
What is Connect Biopharma Holdings Ltd(CNTB)'s stock price today?
The current price of CNTB is $1.30. The 52 week high of CNTB is $3.82 and 52 week low is $1.06.
When is next earnings date of Connect Biopharma Holdings Ltd(CNTB)?
The next earnings date of Connect Biopharma Holdings Ltd(CNTB) is 2026-11-12 Est..
Does Connect Biopharma Holdings Ltd(CNTB) pay dividends? If so, how much?
Connect Biopharma Holdings Ltd(CNTB) does not pay dividend.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers